TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE
This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
16.07.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.
La présente invention concerne des méthodes et des matériaux pour traiter des mammifères ayant, ou présentant un risque de développer, un ou plusieurs troubles du mouvement (par exemple, un tremblement essentiel, l'épilepsie et/ou la maladie de Parkinson). L'invention concerne par exemple des compositions comprenant un ou plusieurs antagonistes du canal calcique de type T (par exemple, un ou plusieurs antagonistes Cav3 tels que CX-8998) ainsi que des procédés d'administration de ces compositions à un mammifère ayant, ou présentant un risque de développer, un ou plusieurs troubles du mouvement (par exemple, un tremblement essentiel, l'épilepsie et/ou la maladie de Parkinson) pour traiter le mammifère. |
---|---|
Bibliography: | Application Number: WO2019US54498 |